Administration, Evaluation and Planning

$287,215U54FY2012CANIH

Sarc, Ann Arbor MI

Investigators

Linked publications & trials

Paper 37052491 Paper 36240209 Paper 36162051 Paper 33335088 Paper 33289920 Paper 32651460 Paper 32544094 Paper 31636198 Paper 31521948 Paper 31387924 Paper 31112524 Paper 30980399 Paper 30792533 Paper 30473623 Paper 30192230 Paper 29983640 Paper 29672864 Paper 29499154 Paper 29386236 Paper 29240584 Paper 29108279 Paper 29108227 Paper 28877055 Paper 28851813 Paper 28732326 Paper 28708250 Paper 28632504 Paper 28614716 Paper 28588009 Paper 28493547 Paper 28323337 Paper 28279710 Paper 28270683 Paper 28196207 Paper 28184331 Paper 27941796 Paper 27888797 Paper 27874193 Paper 27837031 Paper 27810924 Paper 27807188 Paper 27761835 Paper 27664537 Paper 27601584 Paper 27573658 Paper 27566104 Paper 27528222 Paper 27523972 Paper 27376027 Paper 27364557 Paper 27351911 Paper 27173057 Paper 27165358 Paper 27165356 Paper 27140314 Paper 27116634 Paper 27049730 Paper 27014915 Paper 26962161 Paper 26918731 Paper 26908627 Paper 26806808 Paper 26802024 Paper 26796306 Paper 26795289 Paper 26790525 Paper 26710211 Paper 26646755 Paper 26627009 Paper 26601204 Paper 26585554 Paper 26554828 Paper 26475335 Paper 26396249 Paper 26364859 Paper 26355893 Paper 26349414 Paper 26349011 Paper 26297069 Paper 26222502 Paper 26200462 Paper 26181268 Paper 26101897 Paper 26079799 Paper 26078988 Paper 26066736 Paper 26052443 Paper 26006023 Paper 25961935 Paper 25931818 Paper 25890085 Paper 25888633 Paper 25865047 Paper 25852058 Paper 25781619 Paper 25610746 Paper 25536954 Paper 25535838 Paper 25387699 Paper 25374341

Abstract

The Administration Core (Core A) will coordinate and support the programmatic, fiscal, oversight and developmental endeavors upon which the translational success of the SARC Sarcoma SPORE depends. The goals of the SPORE are to translate biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and particularly -advances in the treatment of sarcoma. The SARC Sarcoma SPORE is anchored by multiple researchers from SARC, Harvard, and MD Anderson Cancer Center, but also includes key individual researchers from Stanford University, Columbia University and The University of Michigan. The researchers represent medical and pediatric oncology and the projects explore both soft tissue and bone sarcomas. Four major projects are proposed: 1) Rational HDACi-based therapeutic strategies for the treatment of genetically complex STS; 2) Developing effective combination therapies for malignant peripheral nerve sheath tumor (MPNST); 3) Identification of biomarkers of response to G-protein coupled receptors and novei therapeutic targets in Ewing's sarcoma; and 4) Developing quantitative imaging biomarkers for assessing therapeutic response to sarcoma therapy. These projects are integrated and supported by 4 cores: 1) Administration, Evaluation and Planning; 2) Tissue and Pathology; 3) Clinical Trials; and 4) Biostatistics. The SP0RE application outlines a Developmental Research Program that includes a plan for selection of new projects as well as 14 proposed developmental pilot projects. We also inciude a Career Development Program that outlines a mechanism for the identification and support of talented young investigators in translational or clinical sarcoma research. The projects and cores proposed in this application are highly integrated and are poised to take maximum advantage ofthe SPORE mechanism to achieve translational goals. This SPORE joins the foremost sarcoma investigators and state-of-the art research projects with the multi-institution, collaborative strength of SARC and commitments from leading institutions to produce successful translational advances in the diagnosis, treatment, and prevention of sarcoma.

View original record on NIH RePORTER →